• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles Benzothiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles

Professional Introduction to 7-bromo-1,3-benzothiazole (CAS No. 767-70-4)

7-bromo-1,3-benzothiazole, with the chemical formula C?H?BrN?S, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical and chemical research. This compound is characterized by its bromine substituent on the benzothiazole core, which makes it a versatile intermediate in the synthesis of various bioactive molecules. TheCAS No. 767-70-4 uniquely identifies this substance and underscores its importance in industrial and academic settings.

The benzothiazole scaffold is a privileged structure in medicinal chemistry due to its broad spectrum of biological activities. It is commonly found in numerous pharmacologically active agents, including antimicrobial, antiviral, anti-inflammatory, and anticancer drugs. The introduction of a bromine atom at the 7-position of the benzothiazole ring enhances its reactivity and utility in further derivatization, making it a valuable building block for drug discovery efforts.

In recent years, there has been a surge in research focused on developing novel therapeutic agents derived from benzothiazole derivatives. The7-bromo-1,3-benzothiazole serves as a crucial precursor in synthesizing complex molecules that target specific disease pathways. For instance, studies have demonstrated its role in generating compounds that exhibit potent inhibitory effects on enzymes such as tyrosine kinases and proteases, which are implicated in cancer progression.

One of the most compelling aspects of7-bromo-1,3-benzothiazole is its ability to undergo various chemical transformations, including nucleophilic aromatic substitution, cross-coupling reactions, and cyclization processes. These reactions enable the construction of diverse molecular architectures with tailored biological properties. Researchers have leveraged these synthetic possibilities to develop new analogs with enhanced pharmacokinetic profiles and reduced toxicities.

The pharmaceutical industry has shown particular interest in7-bromo-1,3-benzothiazole due to its potential as a lead compound for drug development. Preclinical studies have highlighted its efficacy in models of inflammation and neurodegeneration. For example, derivatives of this compound have been investigated for their ability to modulate inflammatory cytokine production and protect against oxidative stress-induced neuronal damage.

Moreover, theCAS No. 767-70-4-identified compound has found applications beyond traditional pharmaceuticals. It is increasingly used in materials science for the development of organic semiconductors and luminescent materials. The bromine substituent facilitates further functionalization, allowing chemists to design molecules with specific electronic and optical properties.

The synthesis of7-bromo-1,3-benzothiazole typically involves multi-step organic reactions starting from commercially available precursors such as thiourea and bromobenzene derivatives. Advances in synthetic methodologies have improved the efficiency and scalability of these processes, making it more accessible for large-scale production. This accessibility is crucial for supporting both academic research and industrial applications.

In conclusion, 7-bromo-1,3-benzothiazole (CAS No. 767-70-4) is a multifaceted compound with significant implications in pharmaceutical chemistry and materials science. Its unique structural features and reactivity make it an indispensable tool for researchers seeking to develop novel therapeutic agents and functional materials. As scientific understanding continues to evolve, theCAS No. 767-70-4-denoted compound will undoubtedly remain at the forefront of innovation in these fields.

• 1188090-10-9(2,7-Dibromobenzothiazole)
• 603305-89-1(7-bromothieno3,2-bpyridine)
• 1190322-01-0(5,7-Dibromo-2-chlorobenzodthiazole)
• 767-68-0(4-Bromo-1,3-benzothiazole)
• 110704-32-0(7-bromo-2-methyl-1,3-benzothiazole)
• 1188227-29-3(7-Bromo-2-chlorobenzothiazole)
• 768-11-6(5-bromo-1,3-benzothiazole)
• 53218-26-1(6-Bromobenzothiazole)
• 769-20-0(6-Amino-7-bromobenzothiazole)
• 20358-05-8(7-Bromo-1,3-benzothiazol-2-amine)